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47 Bronchitol (inhaled dry powder mannitol) in adult patients with
cystic ﬁbrosis
M. Aitken1, D. Bilton2, H. Fox3, B. Charlton3, CF-301 & CF-302 Study
Investigators. 1University of Washington, Division of Pulmonary and Critical Care
Medicine, Seattle, United States; 2Royal Brompton Hospital & Hareﬁeld NHS
Foundation Trust, Department of Respiratory Medicine, London, United Kingdom;
3Pharmaxis Ltd, Frenchs Forest, Australia
Introduction: Cystic ﬁbrosis (CF) has a high unmet clinical need for safe, durable
treatments that target the pathophysiologic basis of CF-related disease. Bronchitol
was recently granted EU marketing authorisation for use in adult patients with CF,
in conjunction with standard of care. Two pivotal studies provide an opportunity to
assess Bronchitol’s effect in the approved population.
Methods: Pooled data from two similar multicenter, double-blind, randomized (3:2),
controlled, parallel group phase III studies in which a total of 341 adult patients
(18 yrs) received either Bronchitol 400mg or control (Bronchitol 50mg) bid for
26 weeks.
Results: Adult treatment and control groups were well matched at BL for age
(mean 28.5 yrs), BMI (22.4 kg/m2), gender (57% male), FEV1 (2.27L), concurrent
rhDNase use (61%), nebulised antibiotic use (57%) and P. aeruginosa (65%). Mean
change in FEV1 (mL) from baseline for Bronchitol versus control was statistically
signiﬁcant (99.50mL p< 0.001) over 26 weeks of treatment. Overall treatment effect
on FVC also favoured Bronchitol over control (128.32mL p< 0.001). Exacerbation
incidence reduced by 24% (RR 0.76, 95%CI 0.51 to 1.13) compared to control.
Importantly, Signiﬁcant differences in sputum weights between groups were seen
at all time points with the higher sputum weights in the Bronchitol group reﬂecting
increased MCC (7gms, p< 0.0001).
Conclusion: Bronchitol treatment is associated with sustained and signiﬁcant
improvements in lung function and reductions in pulmonary exacerbations and
associated antibiotic treatment, even when administered as an add-on therapy to
current best standard of care in adult patients with CF.
48 Inhaled 7% hypertonic saline in infants with cystic ﬁbrosis: is it
safe and tolerable?
A. Teper1, J. Balinotti1, V.A. Rodriguez1, S.M. Zaragoza1, S.L. Lubovich1,
C. Kofman1. 1Hospital de Nin˜os Ricardo Guitie´rrez, Centro Respiratorio, Buenos
Aires, Argentina
Background: Hypertonic saline (HS) by rehydrating airway secretions through
osmotic forces increases the volume of airway surface liquid, restoring mucus
clearance and improving lung function in cystic ﬁbrosis (CF) patients. Some studies
have reported marked airway narrowing immediately after inhalation of the ﬁrst dose
HS, even when a bronchodilator is used as premedication.
Objective: To evaluate the safety and tolerability of a single administration of 7%
HS in CF infants.
Subjects and Methods: In sleeping infants and toddlers with conﬁrmed CF,
we measured lung function using the partial volume rapid thoracoabdominal
compression technique. Respiratory symptoms, heart rate, respiratory rate and
oxygen, saturation were recorded throughout the entire study. After completion
of the baseline tests, patients were randomized to receive 3ml of 7%HS or 0.9%
Normal Saline (0.9%NS) both with 0.25mg/kg of salbutamol.
Results: Complete measurements were obtained in 18 infants. Ten infants (mean
age 10 months, range 3−17) received 7% HS and 8 infants (mean age 16 months,
range 4−35) received 0.9%NS. Weight, length, respiratory and heart rate, and
oxygen saturation were not statistically different in both groups. After treatment,
percentage of change of: V′maxFRC (+29% and +34%), respiratory rate (−4%
and +1%), oxygen saturation (−0.5% and 0%) for 7%HS and 0.9%NS respectively
were not statistically different. Two patients from the 7%HS group, both with low
baseline pulmonary function, presented spontaneously reversed wheezing without
hypoxemia.
Conclusions: Inhalation of a single dose of 7% hypertonic saline in CF infants was
tolerable and safe.
49 Modiﬁed nasal catheter for measurement of nasal potential
difference improves repeatability
F. Vermeulen1, J. Ophoff1, M. Proesmans1, L.J. Dupont2, K. De Boeck1.
1University of Leuven, Pediatric Pulmonology, Leuven, Belgium; 2University of
Leuven, Pulmonology, Leuven, Belgium
Nasal potential difference (PD) measurement evaluates changes in chloride transport
through respiratory epithelia of CF subjects induced by novel treatments. Poor
reproducibility of PD measurement hampers its use. We investigated if repeatability
could be improved by measuring PD over a large area.
Methods: A new ’large surface catheter’ (LCS) was designed with a 360º contact
area over 2 cm and was used to measure PD in one nostril while, in the other,
a ‘conventional’ catheter with a small side hole (SHC) was used. Thirty control
subjects and 10 patients with CF were measured twice with both catheters (median
interval 2 days).
Results: Measurement of total chloride response(TCR) with the LSC on a ﬁxed
location (3 cm from nasal margin) vs the SHC on the place of most negative PD
resulted in:
– Better correlation between 1st and 2d measurement (R = 0.85 vs 0.57, p = 0.01)
– Lower within-subject variance (21.3 vs 143.0mV2, p< 0.001)
– Lower TCR values (−14.0±9.1mV vs −21.5±15.9mV, p = 0.01)
If TCR was measured with the LSC on the place of most negative potential vs ﬁxed
location, correlation between 1st and 2d measurement was worse, with only a small
increase in TCR values (−10.9±5.0mV vs −15.2±7.7mV, p = 0.04).
Power calculations favor the use of the LSC (nnt = 18 vs 28 for a correction to
33% of TCR in normal subjects).
Discrimination between CF and controls was slightly better with the LSC (Speci-
ﬁcity of 100% vs 89%, for a sensitivity of 100%).
Conclusion: Measurements of nasal PD with a large contact area on a constant
place have a better repeatability than measurements done with the small routinely
used sidehole catheter, while retaining optimal diagnostic accuracy.
50 Nasal potential measurements: repeatability and reproducibility of
TCS in patients homozygous for the F508del mutation and healthy
controls
A. Leonard1, F. Vermeulen2, K. De Boeck2, T. Leal1, P. Lebecque1. 1University
of Louvain, CF Unit, Cliniques St Luc, Brussels, Belgium; 2University of Leuven,
Pediatric Pulmonology, Leuven, Belgium
Background: The postulate of most clinical studies towards a cure for CF lung
disease has been that an effective agent has to improve chloride secretion (TCS) as
assessed in vivo by nasal potential difference (NPD) measurements. Yet TCS is not
a very robust tool and data on variability of NPD measurements remain limited.
Objectives: In order to optimize power calculations of future studies, we aimed
to assess the repeatability and reproducibility of TCS measurements, focusing to
patients homozygous for the F508del mutation.
Methods: Under stable conditions and using the latest standardized operating
procedure (SOP), NPD measurements were performed in duplicate by 2 skilled
operators, 1 month apart, in 35 young adults homozygous for the F508del mutation
and 30 healthy controls. Eleven patients were previously studied in duplicate using
a local setup, providing an opportunity to further analyse the impact of the SOP on
measurements.
Results: Interim analysis showed that
a. 5−10% of tracings have to be rejected on the basis of predeﬁned quality criteria.
b. comparative analysis of 11 patients tested twice in a previous trial using the local
setup evidenced that adoption of the SOP resulted in signiﬁcantly less negative
TCS (p< 0.002) suggesting that “residual chloride secretion” reported in 5−20%
of patients in some studies is mainly related to technical factors.
c. TCS values obtained from right and left nostrils were similar but as expected
averaging them signiﬁcantly reduced between-test variation in a given patient.
Deﬁnitive results will be presented at the conference.
